SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) — OpenAI aims to go beyond a conversational assistant with the announcement of a new ChatGPT feature: the ability to recommend products and complete purchases directly within the chat. Anticipating the competitive advantage this innovation brings to retail, one of AI/R Company's subsidiaries, Avenue Code, today launched a […]
(NasdaqGM:CRVS), SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition GlobeNewswire November 03, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its
Quicksburg, VA – AD Engineering, a leading supplier of high-performance HVAC products and components, is setting a new benchmark for customer satisfaction with faster lead times and transparent pricing. Known for its precision-engineered linesets and minisplit supplies, AD Engineering continues to push industry standards by focusing on clarity, consistency, and reliable service for HVAC professionals
(NASDAQ:PRLD), WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company's JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral presentation at the
(NASDAQ:COGT), Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA) filing for NonAdvSM remains on track for year-end 2025 Multiple bezuclastinib abstracts selected for presentation at the 67th Annual Meeting of the American Society
(NASDAQ:AGIO), CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 67th American Society of
SANTA CLARA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Cloudera, the only company that brings AI to data anywhere, announced today that it has been named a leader in The Forrester Wave(TM): Data Fabric Platforms, Q4 2025 report. According to the report, “Cloudera is an ideal choice for organizations that want robust data processing, scalable
AI/R's Avenue Code Launches ChatGPT Commerce Solution GlobeNewswire November 03, 2025 SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) — OpenAI aims to go beyond a conversational assistant with the announcement of a new ChatGPT feature: the ability to recommend products and complete purchases directly within the chat. Anticipating the competitive advantage this innovation brings to
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results GlobeNewswire November 03, 2025 Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA) filing for NonAdvSM remains on track for year-end 2025